MUMBAI, Feb. 22 (Xinhua) -- India's drug maker Glenmark Pharmaceuticals has received marketing approval from the Russian health ministry to sell its novel fixed dose combination nasal spray, according to its corporate filing on Monday.
The nasal spray, indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age, relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
Allergic rhinitis, which can impact a person's quality of life and lead to functional impairments, as well as increase the risk of having asthma, is said to affect a certain proportion of the Russian population.
"This new innovative addition to our portfolio is yet another major step in strengthening Glenmark's respiratory focus in Russia and the CIS ( the Commonwealth of Independent States) region. Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country," said Csaba Kantor, senior vice president and head for the Russia and CIS region at the Mumbai-headquartered Glenmark Pharmaceuticals, which has annual revenues of 1.3 billion U.S. dollars. Enditem
